Matthew D. Galsky, MD, on Key Takeaways From 2021 ASCO Annual Meeting in Bladder Cancer

CancerNetwork® sat down with Matthew D. Galsky, MD, at the 2021 ASCO Annual Meeting to discuss his thoughts on research he believes has the greatest potential to impact standard of care treatment of bladder cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Matthew D. Galsky, MD, of Mount Sinai Hospital in New York, regarding bladder-sparing approaches to bladder cancer and how new data may motivate more clinicians to utilize these treatment strategies. Galsky and colleagues presented findings from a study combining bladder-sparing surgery and systemic neoadjuvant therapy with nivolumab and chemotherapy.


I think that the biggest impact from studies at ASCO this year in the bladder cancer field probably have to do with bladder-sparing approaches. They really mark a new dawn in bladder-sparing approaches in bladder cancer in terms of integrating immune checkpoint blockade with radiation, or even without radiation in terms of trying to achieve bladder sparing. This is an approach that’s, of course, been used for decades. It is standard of care. There’s level one evidence for the approach, although it’s not practiced as frequently in some parts of the world as others. It could be that the integration of a new treatment modality into the bladder-sparing arena is a tipping point that is needed to really [motivate] the community to embrace this as a reasonable option for patients with bladder cancer.


Galsky MD, Daneshmand S, Chan KG, et al. Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC): HCRN GU 16-257. J Clin Oncol. 2021;39(suppl 15):4503. doi:10.1200/JCO.2021.39.15_suppl.4503

Related Videos
A recovery tracker and other digital tools may be useful in helping to manage patient symptoms following debulking surgery for gynecologic cancer, according to an expert from Memorial Sloan Kettering Cancer Center.
Common symptoms following debulking surgery for gynecologic cancer appear to include pain, diarrhea, and nausea, according to an expert from Memorial Sloan Kettering Cancer Center.
Patients who use a recovery tracker tool appear to experience lower hospital readmission rates following gynecologic cancer debulking surgery compared with those who did not.
Medical oncologists and gynecologic oncologists alike have a shared responsibility to help treat symptoms of neuropathy in patients undergoing chemotherapy for gynecologic cancer, according to an expert from Duke University Medical Center.
Future research assessing cryocompression for those with gynecologic cancers will make use of different products to make the intervention easier and more accessible for patients.
Cryocompression demonstrates potential for preventing chemotherapy-induced neuropathy for those with gynecologic cancers, according to an expert from Duke University Medical Center.
The addition of radiation to chemotherapy did not improve overall survival in patients with advanced endometrial cancer, according to an expert from Northwestern Medicine.
Nazy Zomorodian, NP, spoke with CancerNetwork® about the unique dosing schedule of enfortumab vedotin plus pembrolizumab following its accelerated approval by the FDA in advanced/metastatic urothelial cancer.
An expert from Dana-Farber Cancer Institute indicates that urologists should refer patients with prostate cancer who present with multiple high-risk factors at surgery to a radiation and medical oncologist.
Fifteen-year results of the ProtecT prostate cancer trial may support the findings of the study’s 10-year follow-up data, according to an expert from Dana-Farber Cancer Institute.
Related Content